Summary
- Current Price
- As of today, DXCM price is $84.75, up +2.08% on
- Current Price All-Time High
- DXCM price is currently -48.59% below its historical high of $164.86 set on
- Market Cap
- DXCM current market cap is $32B, up +6.73% over the past 365 days
- PE Ratio
- DXCM current PE ratio is 33.45
- Revenue
- DXCM current annual revenue is $4.66B, up +15.60% year-over-year
- Next Earnings
- The next earnings release for DXCM is on
Profile
| Metric | Value |
|---|---|
| Full Name | DexCom, Inc. |
| Ticker | NASDAQ: DXCM |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Country | United States |
| IPO | |
| Indexes | |
| Website | dexcom.com |
| Employees | 10,200 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $84.75 | |
| Price, 1D Change | +2.08% | |
| Market Cap | $32B | |
| - | ||
| PE Ratio | 33.45 | |
| Beta | 0.75 | |
| Revenue | $4.66B | |
| Revenue, 1Y Change | +15.60% | |
| EPS | $2.09 | |
| EPS, 1Y Change | +46.73% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 4:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $2.09 | |
| EPS Estimate | $2.66 | N/A |
| EPS Est. Change | +27.45% | N/A |
| Revenue | $4.66B | |
| Revenue Estimate | $5.23B | N/A |
| Revenue Est. Change | +12.19% | N/A |
| Current Price | $84.75 | |
| Price Target | $93.00 | - |
| Price Tgt. Change | +9.73% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.69 | $1.42 | -15.54% | |
| $2.07 | $2.09 | +0.83% | |
| $2.66 | N/A | +27.45% | |
| $3.13 | N/A | +49.60% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.02B | $4.03B | +0.25% | |
| $4.66B | $4.66B | +0.15% | |
| $5.23B | N/A | +12.19% | |
| $5.80B | N/A | +24.42% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +10.93% | |
| Price, 3Y | -29.94% | |
| Market Cap, 1Y | +6.73% | |
| Market Cap, 3Y | -31.53% | |
| Revenue, 1Y | +15.60% | |
| Revenue, 3Y | +60.22% | |
| EPS, 1Y | +46.73% | |
| EPS, 3Y | +161.81% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $84.75 | |
| SMA 200 | $68.20 | |
| SMA 50 | $74.47 | |
| EMA 200 | $71.14 | |
| EMA 50 | $74.53 | |
| MACD | $3.20 | |
| Beta | 0.75 | |
| ATR | $3.09 | |
| 14-Day RSI | 64.35 | |
| 10-Day Volatility | 69.48% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $4.66B | |
| EPS | $2.09 | |
| Gross Profit | $2.80B | |
| Gross Margin | 60.01% | |
| Operating Income | $911.80M | |
| Operating Margin | 19.56% | |
| Net Income | $836.30M | |
| Net Margin | 17.94% | |
| EBITDA | $1.16B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.51 | |
| 1.88 | ||
| 1.59 | ||
| - | ||
| 8 | ||
| 7.44 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 33.45 | |
| 6.44 | ||
| 12.20 | ||
| 22.40 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $2.75B | |
| $2.00B | ||
| $6.34B | ||
| $4.03B | ||
| $3.59B | ||
| $2.14B | ||
| Total Debt | $1.39B | |
| $21.60M | ||
| $344.30M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $3.83B | ||
| $1.89B | ||
| $1.86B | ||
| $1.29B | ||
| $251.80M | ||
| $0.00 | ||
| $252.10M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $1.44B | ||
| $536.00M | ||
| -$1.69B | ||
| Capex | $363.50M | |
| $1.08B |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Argus Research | → | |
| Canaccord Genuity | → | |
| Wells Fargo | → | |
| Truist Securities | → | |
| Stifel | → | |
| RBC Capital | → | |
| Piper Sandler | → | |
| Mizuho | → | |
| JP Morgan | → | |
| Citigroup | → |
Analyst sentiment
Institutional ownership
No data
Screeners with DXCM
FAQ
- What is the ticker symbol for DexCom, Inc.?
- The ticker symbol for DexCom, Inc. is NASDAQ:DXCM
- Does DexCom, Inc. pay dividends?
- No, DexCom, Inc. does not pay dividends
- What sector is DexCom, Inc. in?
- DexCom, Inc. is in the Healthcare sector
- What industry is DexCom, Inc. in?
- DexCom, Inc. is in the Medical Devices industry
- What country is DexCom, Inc. based in?
- DexCom, Inc. is headquartered in United States
- When did DexCom, Inc. go public?
- DexCom, Inc. initial public offering (IPO) was on April 14, 2005
- Is DexCom, Inc. in the S&P 500?
- Yes, DexCom, Inc. is included in the S&P 500 index
- Is DexCom, Inc. in the NASDAQ 100?
- Yes, DexCom, Inc. is included in the NASDAQ 100 index
- Is DexCom, Inc. in the Dow Jones?
- No, DexCom, Inc. is not included in the Dow Jones index
- When was DexCom, Inc. last earnings report?
- DexCom, Inc.'s most recent earnings report was on July 30, 2026
- When does DexCom, Inc. report earnings?
- The next expected earnings date for DexCom, Inc. is October 29, 2026
Data Sources & References
- DXCM Official Website www.dexcom.com/global
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1093557/000109355726000027/0001093557-26-000027-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- List of NASDAQ 100 Companies www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index
- DXCM Profile on Yahoo Finance finance.yahoo.com/quote/DXCM
- DXCM Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/dxcm